Develops and sells noninvasive neurostimulation treatments for mental health and neurological disorders. Now — the numbers.
This is an established company with proven profits.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $62.3M would still be left in the vault — a solid cushion for hard times.
The market pays 73.5× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
Over the last 4 years, sales grew about 18% a year on average.
There is $69.1M in the vault; even if every debt were paid off, $62.3M would remain.
The company’s market value is 73 times its annual profit. Even a small disappointment could hit the price hard.
The price action doesn’t yet back an upward turn. Council score: 0/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.